Abstract
Nucleophosmin (NPM1) is a nuclear protein that is mutated and localized in cytoplasm in approximately 30% of acute myeloid leukemia (AML) and 50% to 60% of cytogenetically normal AML. The goal of the study is to evaluate whether subcellular localization of NPM1 by IHC is stable in AML patients and whether detection of NPMc+ by IHC is useful …
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
